Last 165.45 INR
Change Today -3.95 / -2.33%
Volume 366.7K
JOL On Other Exchanges
Symbol
Exchange
Natl India
As of 6:06 AM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

jubilant life sciences ltd (JOL) Snapshot

Open
172.00
Previous Close
169.40
Day High
172.00
Day Low
164.30
52 Week High
06/13/14 - 222.00
52 Week Low
02/20/14 - 111.00
Market Cap
26.4B
Average Volume 10 Days
884.9K
EPS TTM
6.85
Shares Outstanding
159.3M
EX-Date
08/21/14
P/E TM
24.2x
Dividend
3.00
Dividend Yield
1.81%
Current Stock Chart for JUBILANT LIFE SCIENCES LTD (JOL)

Related News

No related news articles were found.

jubilant life sciences ltd (JOL) Related Businessweek News

No Related Businessweek News Found

jubilant life sciences ltd (JOL) Details

Jubilant Life Sciences Limited, an integrated pharmaceutical and life sciences company, manufactures and supplies pharmaceutical and life sciences products and services worldwide. The company provides active pharmaceutical ingredients (APIs) for cardiovascular system (CVS) and central nervous system (CNS), as well as anti-infective and anti-ulcerants. Its APIs include solid dosage formulations for CVS, CNS, and anti-allergy categories; radiopharmaceuticals for the diagnosis, treatment, and monitoring of diseases; and allergy therapy products, including allergenic extracts and mixes, and skin test devices. The company also offers life sciences ingredients, such as pyridine and picoline; fine chemicals; crop science chemicals; nutrition products, including niacinamide, niacin (vitamin B3), and choline chloride; animal nutrition products in the category of vitamin and mineral premixes, betaine, acidifiers, toxin binders, growth promoters, and emulsifiers; acetyl products, which include acetic acid, monochloro acetic acid, acetic anhydride, ethyl acetate, and sodium mono chlor acetate; and specialty gases, such as liquid carbon dioxide and ethylene oxide mixtures. In addition, it provides contract manufacturing services in manufacturing sterile injectables, and solid and semi solid dosage forms; drug discovery services in bioinformatics, chemoinformatics, and crystallography structure directed molecular design and information technology; pre clinical services, such as medicinal chemistry, analytical chemistry, custom synthesis, library design, and clinical development and market launch services; and conducts integrated drug discovery and development programs on oncology, metabolic disorders, pain, and inflammation. The company was formerly known as Jubilant Organosys Limited and changed its name to Jubilant Life Sciences Limited in 2010. Jubilant Life Sciences Limited was incorporated in 1978 and is based in Noida, India.

6,200 Employees
Last Reported Date: 10/28/14
Founded in 1978

jubilant life sciences ltd (JOL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jubilant life sciences ltd (JOL) Key Developments

Jubilant Life Sciences, Aurobindo and Lupin Receive US FDA Approval to Produce Generic Versions of Novartis' Diovan Hypertension Treatment

Jubilant Life Sciences, Aurobindo and Lupin Pharmaceutical - have received final US FDA approval to produce a generic equivalent of Novartis' (Switzerland) Diovan (valsartan) drug, which is indicated for the treatment of hypertension, blood pressure and heart failure. Israel's Teva also recently announced its intention to launch a generic version of Diovan. Lupin pharmaceutical and Jubilant have announced that they are ready to launch valsartan on the US market in strengths of 40 mg, 80 mg 160 mg and 320 mg.

Jubilant Life Sciences Limited Appoints Executives

Jubilant Life Sciences Limited appointed Mr. Pramod Yadav and Mr. Rajesh Srivastava as co-CEOs of the Life Science Ingredients business of company.

Jubilant Life Sciences Ltd Receives ANDA Approvals for Mycophenolate Mofetil and Rizatriptan

Jubilant Life Sciences Ltd. has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Mycophenolate Mofetil USP, 250 mg Capsules and 500 mg Tablets and Rizatriptan Tablets 5 mg and 10 mg. Mycophenolate Mofetil USP, 250 mg Capsules and 500 mg Tablets is the generic version of Cellcept® (of Roche), an immunosuppressant which is used to help prevent organ rejection in transplants. The current annualized US market size for Mycophenolate Mofetil USP, 250 mg Capsules and 500 mg Tablets as per IMS is USD 245 Million. Rizatriptan Tablets 5 mg and 10 mg is the generic version of Maxalt® (of Merck), used for the treatment of migraine. The current annualized US market size for Rizatriptan Tablets 5 mg and 10 mg as per IMS is USD 70 Million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JOL:IN 165.45 INR -3.95

JOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dishman Pharmaceuticals & Chemicals Ltd 136.25 INR 0.00
Glenmark Pharmaceuticals Ltd 724.25 INR 0.00
Piramal Enterprises Ltd 834.95 INR 0.00
Shasun Pharmaceuticals Ltd 283.60 INR 0.00
Torrent Pharmaceuticals Ltd 1,143 INR 0.00
View Industry Companies
 

Industry Analysis

JOL

Industry Average

Valuation JOL Industry Range
Price/Earnings 17.4x
Price/Sales 0.5x
Price/Book 1.0x
Price/Cash Flow 6.1x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JUBILANT LIFE SCIENCES LTD, please visit www.jubl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.